Post-Cardiac Arrest Syndrome (PCAS) - Market Insights, Epidemiology and Market Forecast-2027
This report can be delivered to the clients within 24 hours
DelveInsight’s ‘Post-Cardiac Arrest Syndrome (PCAS) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PCAS in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of PCAS from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
Post-Cardiac Arrest Syndrome (PCAS) - Disease Understanding and Treatment Algorithm
The DelveInsight PCAS market report gives the thorough understanding of the PCAS by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for PCAS in the US, EU5, and Japan.
Post-Cardiac Arrest Syndrome Epidemiology
The Post-Cardiac Arrest Syndrome epidemiology division provide the insights about historical and current patient pool and forecasted trend for seven major markets. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total Diagnosed Incident cases, Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (OHSCA) Cases, Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) cases), scenario of PCAS in the seven major markets covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, total diagnosed incident population of Post-Cardiac Arrest Syndrome in the 7 major markets was found to be 1,150,165 in 2016.
Post-Cardiac Arrest Syndrome (PCAS) Drug Chapters
This segment of the PCAS report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current therapeutic market in 7MM is driven majorly by mechanical ventilation and targeted temperature management. Detailed chapter for upcoming therapy like Xenon (NeuroproteXeon/Mallinckrodt) have been covered in the report.
Post-Cardiac Arrest Syndrome Market Outlook
The PCAS market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of PCAS in the 7MM was found to be USD 547.0 million in 2016, and is expected to increase from 2016-2027.
PCAS Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
PCAS Report Insights
DelveInsight’s ‘Post-Cardiac Arrest Syndrome (PCAS) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PCAS in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of PCAS from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Post-Cardiac Arrest Syndrome (PCAS) - Disease Understanding and Treatment Algorithm
The DelveInsight PCAS market report gives the thorough understanding of the PCAS by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for PCAS in the US, EU5, and Japan.
Post-Cardiac Arrest Syndrome Epidemiology
The Post-Cardiac Arrest Syndrome epidemiology division provide the insights about historical and current patient pool and forecasted trend for seven major markets. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total Diagnosed Incident cases, Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (OHSCA) Cases, Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) cases), scenario of PCAS in the seven major markets covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, total diagnosed incident population of Post-Cardiac Arrest Syndrome in the 7 major markets was found to be 1,150,165 in 2016.
Post-Cardiac Arrest Syndrome (PCAS) Drug Chapters
This segment of the PCAS report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current therapeutic market in 7MM is driven majorly by mechanical ventilation and targeted temperature management. Detailed chapter for upcoming therapy like Xenon (NeuroproteXeon/Mallinckrodt) have been covered in the report.
Post-Cardiac Arrest Syndrome Market Outlook
The PCAS market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of PCAS in the 7MM was found to be USD 547.0 million in 2016, and is expected to increase from 2016-2027.
PCAS Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
PCAS Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving PCAS market
- Organize sales and marketing efforts by identifying the best opportunities for PCAS market
- To understand the future market competition in the PCAS market.
1. KEY INSIGHTS
2. PCAS MARKET OVERVIEW AT A GLANCE
2.1. Market Share (%) Distribution of PCAS in 2017
2.2. Market Share (%) Distribution of PCAS in 2027
3. DISEASE OVERVIEW: PCAS
3.1. Introduction
3.2. Phases of the PCAS
3.3. Causes of Sudden Cardiac Arrest
3.4. Risk Factors
3.5. Pathophysiology of PCAS
3.6. Molecular and genetic basis of sudden cardiac death
3.7. Biomarkers
3.8. Diagnosis
3.8.1. Glasgow Coma Scale
3.8.2. Prognosis for Cardiac Arrest Survivors
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. 7MM Total Diagnosed Incident Patient Population of Sudden Cardiac Arrest (SCA)
5. COUNTRY WISE-EPIDEMIOLOGY OF PCAS
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Diagnosed Incident Cases of Sudden Cardiac Arrest in the United States
5.1.3. Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (IHSCA) Cases in the US
5.1.4. Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) Cases in the US
5.2. Germany
5.2.1. Assumptions and Rationale
5.2.2. Diagnosed Incident Cases of Sudden Cardiac Arrest in the Germany
5.2.3. Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Germany
5.2.4. Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Germany
5.3. France
5.3.1. Assumptions and Rationale
5.3.2. Diagnosed Incident Cases of Sudden Cardiac Arrest in France
5.3.3. Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (IHSCA) Cases in France
5.3.4. Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) Cases in France
5.4. Italy
5.4.1. Assumptions and Rationale
5.4.2. Diagnosed Incident Cases of Sudden Cardiac Arrest in Italy
5.4.3. Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Italy
5.4.4. Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Italy
5.5. Spain
5.5.1. Assumptions and Rationale
5.5.2. Diagnosed Incident Cases of Sudden Cardiac Arrest in Spain
5.5.3. Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Spain
5.5.4. Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Spain
5.6. United Kingdom
5.6.1. Assumptions and Rationale
5.6.2. Diagnosed Incident Cases of Sudden Cardiac Arrest in the United Kingdom
5.6.3. Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (IHSCA) Cases in the United Kingdom
5.6.4. Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) Cases in the United Kingdom
5.7. Japan
5.7.1. Assumptions and Rationale
5.7.2. Diagnosed Incident Cases of Sudden Cardiac Arrest in Japan
5.7.3. Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Japan
5.7.4. Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Japan
6. CURRENT TREATMENT PRACTICES
6.1. American Heart Association Guidelines
6.1.1. Post–Cardiac Arrest Care: American Heart Association 2015 Guidelines
6.2. European Resuscitation Council and European Society of Intensive Care Medicine Guidelines for Post-resuscitation Care 2015
6.2.1. Airway and breathing
6.2.2. Circulation
6.2.3. Haemodynamic management
6.2.4. Implantable Cardioverter defibrillators
6.2.5. Disability (optimizing neurological recovery)
6.2.6. Temperature control
6.3. Japan Resuscitation Council Resuscitation Guidelines 2015
7. UNMET NEEDS
8. EMERGING THERAPIES
8.1. Xenon: NeuroproteXeon/ Mallinckrodt
8.1.1. Product Description
8.1.2. Other Developmental Activities
8.1.3. Clinical Development
8.1.4. Safety and Efficacy
8.1.5. Product Profile
9. PCAS: 7 MAJOR MARKET ANALYSIS
9.1. Key Findings
9.2. Market Size of Post-Cardiac Arrest Syndrome in 7MM
10. MARKET OUTLOOK BY COUNTRY
11. THE UNITED STATES: MARKET OUTLOOK
11.1. United States Market Size
11.1.1. Total Market size of Post-Cardiac Arrest Syndrome
11.1.2. Market Size of Post-Cardiac Arrest Syndrome by Therapies
11.2. EU-5 Countries: Market Outlook
11.3. Germany Market Size
11.3.1. Total Market size of Post-Cardiac Arrest Syndrome
11.3.2. Market Size of Post-Cardiac Arrest Syndrome by Therapies
11.4. France Market Size
11.4.1. Total Market size of Post-Cardiac Arrest Syndrome
11.4.2. Market Size of Post-Cardiac Arrest Syndrome by Therapies
11.5. Italy Market Size
11.5.1. Total Market size of Post-Cardiac Arrest Syndrome
11.5.2. Market Size of Post-Cardiac Arrest Syndrome by Therapies
11.6. The United Kingdom Market Size
11.6.1. Total Market size of Post-Cardiac Arrest Syndrome
11.6.2. Market Size of Post-Cardiac Arrest Syndrome by Therapies
11.7. Spain Market Size
11.7.1. Total Market size of Post-Cardiac Arrest Syndrome
11.7.2. Market Size of Post-Cardiac Arrest Syndrome by Therapies
11.8. Japan: Market Outlook
11.9. Japan Market Size
11.9.1. Total Market size of Post-Cardiac Arrest Syndrome
11.9.2. Market Size of Post-Cardiac Arrest Syndrome by Therapies
12. MARKET DRIVERS
13. MARKET BARRIERS
14. APPENDIX
14.1. Report Methodology
15. DELVEINSIGHT CAPABILITIES
16. DISCLAIMER
17. ABOUT DELVEINSIGHT
2. PCAS MARKET OVERVIEW AT A GLANCE
2.1. Market Share (%) Distribution of PCAS in 2017
2.2. Market Share (%) Distribution of PCAS in 2027
3. DISEASE OVERVIEW: PCAS
3.1. Introduction
3.2. Phases of the PCAS
3.3. Causes of Sudden Cardiac Arrest
3.4. Risk Factors
3.5. Pathophysiology of PCAS
3.6. Molecular and genetic basis of sudden cardiac death
3.7. Biomarkers
3.8. Diagnosis
3.8.1. Glasgow Coma Scale
3.8.2. Prognosis for Cardiac Arrest Survivors
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. 7MM Total Diagnosed Incident Patient Population of Sudden Cardiac Arrest (SCA)
5. COUNTRY WISE-EPIDEMIOLOGY OF PCAS
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Diagnosed Incident Cases of Sudden Cardiac Arrest in the United States
5.1.3. Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (IHSCA) Cases in the US
5.1.4. Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) Cases in the US
5.2. Germany
5.2.1. Assumptions and Rationale
5.2.2. Diagnosed Incident Cases of Sudden Cardiac Arrest in the Germany
5.2.3. Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Germany
5.2.4. Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Germany
5.3. France
5.3.1. Assumptions and Rationale
5.3.2. Diagnosed Incident Cases of Sudden Cardiac Arrest in France
5.3.3. Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (IHSCA) Cases in France
5.3.4. Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) Cases in France
5.4. Italy
5.4.1. Assumptions and Rationale
5.4.2. Diagnosed Incident Cases of Sudden Cardiac Arrest in Italy
5.4.3. Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Italy
5.4.4. Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Italy
5.5. Spain
5.5.1. Assumptions and Rationale
5.5.2. Diagnosed Incident Cases of Sudden Cardiac Arrest in Spain
5.5.3. Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Spain
5.5.4. Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Spain
5.6. United Kingdom
5.6.1. Assumptions and Rationale
5.6.2. Diagnosed Incident Cases of Sudden Cardiac Arrest in the United Kingdom
5.6.3. Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (IHSCA) Cases in the United Kingdom
5.6.4. Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) Cases in the United Kingdom
5.7. Japan
5.7.1. Assumptions and Rationale
5.7.2. Diagnosed Incident Cases of Sudden Cardiac Arrest in Japan
5.7.3. Resuscitation of Out-Of-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Japan
5.7.4. Resuscitation of In-Hospital Sudden Cardiac Arrest (IHSCA) Cases in Japan
6. CURRENT TREATMENT PRACTICES
6.1. American Heart Association Guidelines
6.1.1. Post–Cardiac Arrest Care: American Heart Association 2015 Guidelines
6.2. European Resuscitation Council and European Society of Intensive Care Medicine Guidelines for Post-resuscitation Care 2015
6.2.1. Airway and breathing
6.2.2. Circulation
6.2.3. Haemodynamic management
6.2.4. Implantable Cardioverter defibrillators
6.2.5. Disability (optimizing neurological recovery)
6.2.6. Temperature control
6.3. Japan Resuscitation Council Resuscitation Guidelines 2015
7. UNMET NEEDS
8. EMERGING THERAPIES
8.1. Xenon: NeuroproteXeon/ Mallinckrodt
8.1.1. Product Description
8.1.2. Other Developmental Activities
8.1.3. Clinical Development
8.1.4. Safety and Efficacy
8.1.5. Product Profile
9. PCAS: 7 MAJOR MARKET ANALYSIS
9.1. Key Findings
9.2. Market Size of Post-Cardiac Arrest Syndrome in 7MM
10. MARKET OUTLOOK BY COUNTRY
11. THE UNITED STATES: MARKET OUTLOOK
11.1. United States Market Size
11.1.1. Total Market size of Post-Cardiac Arrest Syndrome
11.1.2. Market Size of Post-Cardiac Arrest Syndrome by Therapies
11.2. EU-5 Countries: Market Outlook
11.3. Germany Market Size
11.3.1. Total Market size of Post-Cardiac Arrest Syndrome
11.3.2. Market Size of Post-Cardiac Arrest Syndrome by Therapies
11.4. France Market Size
11.4.1. Total Market size of Post-Cardiac Arrest Syndrome
11.4.2. Market Size of Post-Cardiac Arrest Syndrome by Therapies
11.5. Italy Market Size
11.5.1. Total Market size of Post-Cardiac Arrest Syndrome
11.5.2. Market Size of Post-Cardiac Arrest Syndrome by Therapies
11.6. The United Kingdom Market Size
11.6.1. Total Market size of Post-Cardiac Arrest Syndrome
11.6.2. Market Size of Post-Cardiac Arrest Syndrome by Therapies
11.7. Spain Market Size
11.7.1. Total Market size of Post-Cardiac Arrest Syndrome
11.7.2. Market Size of Post-Cardiac Arrest Syndrome by Therapies
11.8. Japan: Market Outlook
11.9. Japan Market Size
11.9.1. Total Market size of Post-Cardiac Arrest Syndrome
11.9.2. Market Size of Post-Cardiac Arrest Syndrome by Therapies
12. MARKET DRIVERS
13. MARKET BARRIERS
14. APPENDIX
14.1. Report Methodology
15. DELVEINSIGHT CAPABILITIES
16. DISCLAIMER
17. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: PCAS: Pathophysiology, Clinical Manifestations, and Potential Treatments
Table 2: Diagnosed Incident Patient Population of SCA in 7MM (2016-2027)
Table 3: Diagnosed Incident Cases of SCA in the US (2016-2027)
Table 4: Resuscitation of OHSCA Cases in the US (2016-2027)
Table 5: Resuscitation of IHSCA Cases in the US (2016-2027)
Table 6: Diagnosed Incident Cases of SCA in Germany (2016-2027)
Table 7: Resuscitation of OHSCA Cases in Germany (2016-2027)
Table 8: Resuscitation of IHSCA Cases in Germany (2016-2027)
Table 9: Diagnosed Incident Cases of SCA in France (2016-2027)
Table 10: Resuscitation of OHSCA Cases in France (2016-2027)
Table 11: Resuscitation of IHSCA Cases in France (2016-2027)
Table 12: Diagnosed Incident Cases of SCA in Italy (2016-2027)
Table 13: Resuscitation of OHSCA Cases in Italy (2016-2027)
Table 14: Resuscitation of IHSCA Cases in Italy (2016-2027)
Table 15: Diagnosed Incident Cases of SCA in Spain (2016-2027)
Table 16: Resuscitation of OHSCA Cases in Spain (2016-2027)
Table 17: Resuscitation of IHSCA Cases in Spain (2016-2027)
Table 18: Diagnosed Incident Cases of SCA in the UK (2016-2027)
Table 19: Resuscitation of OHSCA Cases in the UK (2016-2027)
Table 20: Resuscitation of IHSCA Cases in the UK (2016-2027)
Table 21: Diagnosed Incident Cases of SCA in Japan (2016-2027)
Table 22: Resuscitation of OHSCA Cases in Japan (2016-2027)
Table 23: Resuscitation of IHSCA Cases in Japan (2016-2027)
Table 24: Post Cardiac Arrest Treatment Algorithm
Table 25: Post-resuscitation Care
Table 26: Xenon, Clinical Trial Description, 2018
Table 27: 7 Major Market Size of PCAS in USD Million (2016-2027)
Table 28: United States Market Size of PCAS in USD Million (2016-2027)
Table 29: United States Market Size of PCAS by Therapies in USD Million (2016-2027)
Table 30: Germany Market Size of PCAS in USD Million (2016-2027)
Table 31: Germany Market Size of PCAS by Therapies in USD Million (2016-2027)
Table 32: France Market Size of PCAS in USD Million (2016-2027)
Table 33: France Market Size of PCAS by Therapies in USD Million (2016-2027)
Table 34: Italy Market Size of PCAS in USD Million (2016-2027)
Table 35: Italy Market Size of PCAS by Therapies in USD Million (2016-2027)
Table 36: United Kingdom Market Size of PCAS in USD Million (2016-2027)
Table 37: United Kingdom Market Size of PCAS by Therapies in USD Million (2016-2027)
Table 38: Spain Market Size of PCAS in USD Million (2016-2027)
Table 39: Spain Market Size of PCAS by Therapies in USD Million (2016-2027)
Table 40: Japan Market Size of PCAS in USD Million (2016-2027)
Table 41: Japan Market Size of PCAS by Therapies in USD Million (2016-2027)
Table 1: PCAS: Pathophysiology, Clinical Manifestations, and Potential Treatments
Table 2: Diagnosed Incident Patient Population of SCA in 7MM (2016-2027)
Table 3: Diagnosed Incident Cases of SCA in the US (2016-2027)
Table 4: Resuscitation of OHSCA Cases in the US (2016-2027)
Table 5: Resuscitation of IHSCA Cases in the US (2016-2027)
Table 6: Diagnosed Incident Cases of SCA in Germany (2016-2027)
Table 7: Resuscitation of OHSCA Cases in Germany (2016-2027)
Table 8: Resuscitation of IHSCA Cases in Germany (2016-2027)
Table 9: Diagnosed Incident Cases of SCA in France (2016-2027)
Table 10: Resuscitation of OHSCA Cases in France (2016-2027)
Table 11: Resuscitation of IHSCA Cases in France (2016-2027)
Table 12: Diagnosed Incident Cases of SCA in Italy (2016-2027)
Table 13: Resuscitation of OHSCA Cases in Italy (2016-2027)
Table 14: Resuscitation of IHSCA Cases in Italy (2016-2027)
Table 15: Diagnosed Incident Cases of SCA in Spain (2016-2027)
Table 16: Resuscitation of OHSCA Cases in Spain (2016-2027)
Table 17: Resuscitation of IHSCA Cases in Spain (2016-2027)
Table 18: Diagnosed Incident Cases of SCA in the UK (2016-2027)
Table 19: Resuscitation of OHSCA Cases in the UK (2016-2027)
Table 20: Resuscitation of IHSCA Cases in the UK (2016-2027)
Table 21: Diagnosed Incident Cases of SCA in Japan (2016-2027)
Table 22: Resuscitation of OHSCA Cases in Japan (2016-2027)
Table 23: Resuscitation of IHSCA Cases in Japan (2016-2027)
Table 24: Post Cardiac Arrest Treatment Algorithm
Table 25: Post-resuscitation Care
Table 26: Xenon, Clinical Trial Description, 2018
Table 27: 7 Major Market Size of PCAS in USD Million (2016-2027)
Table 28: United States Market Size of PCAS in USD Million (2016-2027)
Table 29: United States Market Size of PCAS by Therapies in USD Million (2016-2027)
Table 30: Germany Market Size of PCAS in USD Million (2016-2027)
Table 31: Germany Market Size of PCAS by Therapies in USD Million (2016-2027)
Table 32: France Market Size of PCAS in USD Million (2016-2027)
Table 33: France Market Size of PCAS by Therapies in USD Million (2016-2027)
Table 34: Italy Market Size of PCAS in USD Million (2016-2027)
Table 35: Italy Market Size of PCAS by Therapies in USD Million (2016-2027)
Table 36: United Kingdom Market Size of PCAS in USD Million (2016-2027)
Table 37: United Kingdom Market Size of PCAS by Therapies in USD Million (2016-2027)
Table 38: Spain Market Size of PCAS in USD Million (2016-2027)
Table 39: Spain Market Size of PCAS by Therapies in USD Million (2016-2027)
Table 40: Japan Market Size of PCAS in USD Million (2016-2027)
Table 41: Japan Market Size of PCAS by Therapies in USD Million (2016-2027)
LIST OF FIGURES
Figure 1: Phases of PCAS
Figure 2: Pathophysiology of PCAS
Figure 3: Diagnosed Incident Patient Population of SCA in 7MM (2016-2027)
Figure 4: Diagnosed Incident Cases of SCA in the US (2016-2027)
Figure 5: Resuscitation of OHSCA Cases in the US (2016-2027)
Figure 6: Resuscitation of IHSCA Cases in the US (2016-2027)
Figure 7: Diagnosed Incident Cases of SCA in Germany (2016-2027)
Figure 8: Resuscitation of OHSCA Cases in Germany (2016-2027)
Figure 9: Resuscitation of IHSCA Cases in Germany (2016-2027)
Figure 10: Diagnosed Incident Cases of SCA in France (2016-2027)
Figure 11: Resuscitation of OHSCA Cases in France (2016-2027)
Figure 12: Resuscitation of IHSCA Cases in France (2016-2027)
Figure 13: Diagnosed Incident Cases of SCA in Italy (2016-2027)
Figure 14: Resuscitation of OHSCA Cases in Italy (2016-2027)
Figure 15: Resuscitation of IHSCA Cases in Italy (2016-2027)
Figure 16: Diagnosed Incident Cases of SCA in Spain (2016-2027)
Figure 17: Resuscitation of OHSCA Cases in Spain (2016-2027)
Figure 18: Resuscitation of IHSCA Cases in Spain (2016-2027)
Figure 19: Diagnosed Incident Cases of SCA in the UK (2016-2027)
Figure 20: Resuscitation of OHSCA Cases in the UK (2016-2027)
Figure 21: Resuscitation of IHSCA Cases in the UK (2016-2027)
Figure 22: Diagnosed Incident Cases of SCA in Japan (2016-2027)
Figure 23: Resuscitation of OHSCA Cases in Japan (2016-2027)
Figure 24: Resuscitation of IHSCA Cases in Japan (2016-2027)
Figure 25: Unmet Needs for PCAS
Figure 26: 7 Major Market Size of PCAS in USD Million (2016-2027)
Figure 27: United States Market Size of PCAS in USD Millions (2016-2027)
Figure 28: United States Market Size of PCAS by Therapies in USD Million (2016-2027)
Figure 29: Germany Market Size of PCAS in USD Millions (2016-2027)
Figure 30: Germany Market Size of PCAS by Therapies in USD Million (2016-2027)
Figure 31: France Market Size of PCAS in USD Millions (2016-2027)
Figure 32: France Market Size of PCAS by Therapies in USD Million (2016-2027)
Figure 33: Italy Market Size of PCAS in USD Millions (2016-2027)
Figure 34: Italy Market Size of PCAS by Therapies in USD Million (2016-2027)
Figure 35: United Kingdom Market Size of PCAS in USD Millions (2016-2027)
Figure 36: United Kingdom Market Size of PCAS by Therapies in USD Million (2016-2027)
Figure 37: Spain Market Size of PCAS in USD Millions (2016-2027)
Figure 38: Spain Market Size of PCAS by Therapies in USD Million (2016-2027)
Figure 39: Japan Market Size of PCAS in USD Millions (2016-2027)
Figure 40: Japan Market Size of PCAS by Therapies in USD Million (2016-2027)
Figure 41: Market Drivers
Figure 42: Market Barriers
Figure 1: Phases of PCAS
Figure 2: Pathophysiology of PCAS
Figure 3: Diagnosed Incident Patient Population of SCA in 7MM (2016-2027)
Figure 4: Diagnosed Incident Cases of SCA in the US (2016-2027)
Figure 5: Resuscitation of OHSCA Cases in the US (2016-2027)
Figure 6: Resuscitation of IHSCA Cases in the US (2016-2027)
Figure 7: Diagnosed Incident Cases of SCA in Germany (2016-2027)
Figure 8: Resuscitation of OHSCA Cases in Germany (2016-2027)
Figure 9: Resuscitation of IHSCA Cases in Germany (2016-2027)
Figure 10: Diagnosed Incident Cases of SCA in France (2016-2027)
Figure 11: Resuscitation of OHSCA Cases in France (2016-2027)
Figure 12: Resuscitation of IHSCA Cases in France (2016-2027)
Figure 13: Diagnosed Incident Cases of SCA in Italy (2016-2027)
Figure 14: Resuscitation of OHSCA Cases in Italy (2016-2027)
Figure 15: Resuscitation of IHSCA Cases in Italy (2016-2027)
Figure 16: Diagnosed Incident Cases of SCA in Spain (2016-2027)
Figure 17: Resuscitation of OHSCA Cases in Spain (2016-2027)
Figure 18: Resuscitation of IHSCA Cases in Spain (2016-2027)
Figure 19: Diagnosed Incident Cases of SCA in the UK (2016-2027)
Figure 20: Resuscitation of OHSCA Cases in the UK (2016-2027)
Figure 21: Resuscitation of IHSCA Cases in the UK (2016-2027)
Figure 22: Diagnosed Incident Cases of SCA in Japan (2016-2027)
Figure 23: Resuscitation of OHSCA Cases in Japan (2016-2027)
Figure 24: Resuscitation of IHSCA Cases in Japan (2016-2027)
Figure 25: Unmet Needs for PCAS
Figure 26: 7 Major Market Size of PCAS in USD Million (2016-2027)
Figure 27: United States Market Size of PCAS in USD Millions (2016-2027)
Figure 28: United States Market Size of PCAS by Therapies in USD Million (2016-2027)
Figure 29: Germany Market Size of PCAS in USD Millions (2016-2027)
Figure 30: Germany Market Size of PCAS by Therapies in USD Million (2016-2027)
Figure 31: France Market Size of PCAS in USD Millions (2016-2027)
Figure 32: France Market Size of PCAS by Therapies in USD Million (2016-2027)
Figure 33: Italy Market Size of PCAS in USD Millions (2016-2027)
Figure 34: Italy Market Size of PCAS by Therapies in USD Million (2016-2027)
Figure 35: United Kingdom Market Size of PCAS in USD Millions (2016-2027)
Figure 36: United Kingdom Market Size of PCAS by Therapies in USD Million (2016-2027)
Figure 37: Spain Market Size of PCAS in USD Millions (2016-2027)
Figure 38: Spain Market Size of PCAS by Therapies in USD Million (2016-2027)
Figure 39: Japan Market Size of PCAS in USD Millions (2016-2027)
Figure 40: Japan Market Size of PCAS by Therapies in USD Million (2016-2027)
Figure 41: Market Drivers
Figure 42: Market Barriers
